EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dova Pharmaceuticals's enterprise value is $807.60 Mil.
Dova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 was $-71.43 Mil. Therefore, Dova Pharmaceuticals's EV-to-EBITDA for today is -11.31.
The historical rank and industry rank for Dova Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
DOVA's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.55 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Dova Pharmaceuticals EV-to-EBITDA Historical Data
The historical data trend for Dova Pharmaceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dova Pharmaceuticals's EV-to-EBITDA
For the Biotechnology subindustry, Dova Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dova Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dova Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Dova Pharmaceuticals's EV-to-EBITDA falls into.
Dova Pharmaceuticals's current Enterprise Value is $807.60 Mil.
Dova Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-71.43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dova Pharmaceuticals (NAS:DOVA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Dova Pharmaceuticals's PE Ratio for today is calculated as:
Dova Pharmaceuticals's share price for today is $28.04.
Dova Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.610.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Dova Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Dova Pharmaceuticals (Dova Pharmaceuticals) Business Description
Dova Pharmaceuticals Inc is a United States based clinical-stage pharmaceutical company engaged in developing treatments for patients suffering from orphan diseases. It is focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. The company's drug candidate, avatrombopag, is an orally administered thrombopoietin receptor agonist, or TPO-RA, that it is developing for the treatment of thrombocytopenia. The company's drug candidate, avatrombopag, is designed to mimic the effects of thrombopoietin, in vitro and in vivo. Thrombopoietin is a hormone produced in the liver and kidney that binds to its receptor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DOVA has been successfully added to your 